Teprotumumab-TRBW Drug Asset Due Diligence Report 2026

This Teprotumumab-TRBW Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Teprotumumab-TRBW can convert its Monoclonal antibody profile and IGF-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Teprotumumab-TRBW (query alias: teprotumumab)
Modality / target	Monoclonal antibody; IGF-1R; IGF-1R antagonists
Highest global status	Approved
Originator	Genmab A/S
Active developers	Amgen, Inc., Horizon Therapeutics Ireland DAC, Amgen Australia Pty Ltd.

The MCP disease footprint includes Graves Ophthalmopathy, Ewing Sarcoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07308964	Phase 4	Not yet recruiting	40	Clinical Response
NCT07142642	Phase 1	Completed	20	Maximum Observed Serum Concentration (Cmax) of Teprotumumab
ChiCTR2600127755	Not Applicable	Not yet recruiting	53	Treatment response rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Clinical and Radiographic Response to Teprotumumab in a Single-Center Retrospective Study

Not Applicable; n=51; evaluation: Positive. Reported fields: CAS(average reduction) = 4.0 Unit ( 1.8)

Durability of Teprotumumab for the Treatment of Thyroid Eye Disease (TED) in Clinical Trials

Phase 2; n=112; evaluation: Positive. Reported fields: CAS = 91.2 point improvement

The Effect of Teprotumumab on Thyroid and Ophthalmic Function in Patients with Acute and Chronic Thyroid Eye Disease

Not Applicable; n=26; evaluation: not stated. Reported fields: Adverse Event: hyperglycemia = 19%

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Teprotumumab-TRBW addresses Graves Ophthalmopathy, Ewing Sarcoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-12-12	Amgen Completes Acquisition Of Horizon Therapeutics Plc	Approved	US$28,500.0M stated total
2022-11-23	Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab	Approved	Financial terms not disclosed
2017-05-08	Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease	Phase 2	US$145.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods for the treatment of thyroid eye disease with anti IGF-1r antagonistic antibodies”. The milestone feed surfaced a patent-application signal described as “IGF1r antibodies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO